Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
The capability of soluble CD95L trimers to trigger CD95-associated signaling pathways is drastically increased by oligomerization. The latter can be achieved, for example, by antibodies recognizing a N-terminal epitope tag in recombinant CD95L variants or by genetic engineering-enforced formation of hexamers. Using highly sensitive and accurate binding studies with recombinant CD95L variants equipped with a Gaussia princeps luciferase reporter domain, we found that oligomerization of CD95L has no major effect on CD95 occupancy. This indicates that the higher activity of oligomerized CD95L trimers is not related to an avidity-related increase in apparent affinity and points instead to a crucial role of aggregation of initially formed trimeric CD95L-CD95 complexes in CD95 activation. Furthermore, binding of soluble CD95L trimers was found to be insufficient to increase the association of CD95 with the lipid raft-containing membrane fraction. However, when Gaussia princeps luciferase-CD95L trimers were used as tracers to "mark" inactive CD95 molecules, increased association of these inactive receptors was observed upon activation of the remaining CD95 molecules by help of highly active hexameric Fc-CD95L or membrane CD95L. Moreover, in cells expressing endogenous CD95 and chimeric CD40-CD95 receptors, triggering of CD95 signaling via endogenous CD95 resulted in co-translocation of CD40-CD95 to the lipid raft fraction, whereas vice versa activation of CD95-associated pathways with Fc-CD40L via CD40-CD95 resulted in co-translocation of endogenous CD95. In sum, this shows that signaling-active CD95 molecules not only enhance their own association with the lipid raft-containing membrane fraction but also those of inactive CD95 molecules.
Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Röntgenring 11, 97070 Würzburg, Germany.
Isabell
I
Lang
Andrea
A
Fick
Viktoria
V
Schäfer
Tina
T
Giner
Daniela
D
Siegmund
Harald
H
Wajant
D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D019013:CD40 Antigens / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D003513:Cycloheximide / Q000494:pharmacology; D053222:Fas Ligand Protein / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D057809:HEK293 Cells; D006801:Humans; D019169:Jurkat Cells; D007700:Kinetics; D021962:Membrane Microdomains / Q000378:metabolism*; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011485:Protein Binding / Q000187:drug effects; D055503:Protein Multimerization; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D021381:Protein Transport; D015398:Signal Transduction; D012995:Solubility; D019014:fas Receptor / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
D019013:CD40 Antigens; D053222:Fas Ligand Protein; D008565:Membrane Proteins; D011500:Protein Synthesis Inhibitors; D019014:fas Receptor; D003513:Cycloheximide